Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
Unicycive Therapeutics Stock Performance
NASDAQ:UNCY opened at $0.64 on Tuesday. The firm has a 50-day simple moving average of $0.59 and a 200-day simple moving average of $0.56. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.60. The firm has a market cap of $66.75 million, a P/E ratio of -0.66 and a beta of 2.26.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Unicycive Therapeutics in a research note on Wednesday, January 29th.
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Recommended Stories
- Five stocks we like better than Unicycive Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Overbought Stocks Explained: Should You Trade Them?
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Industrial Products Stocks Investing
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
